When profiled against a larger panel of breast tumor cell lines, CB-839 exhibited anti-proliferative activity against TNBC cell lines but not ER or HER2+ cell lines . unfamiliar function [8, 9]. The GAC isoform is found to be overexpressed in tumors especially in breast tumor wherein the degree of its large quantity correlates strongly with the tumors degree of malignancy [10C12]. Both KGA and GAC are CCT244747 phosphate (Pi) triggered glutaminases. It has been postulated that Pi concentrations increase in the mitochondria under hypoxic conditions as experienced by many tumors therefore prompting activation of GLS [6, 12]. Although F2RL1 glutamine offers been shown to be an essential amino acid in rapidly dividing tumor cells, mutations or amplifications in the glutamine rate of metabolism genes have not been recognized. However, it has been found that genetic alterations in KRAS and MYC signaling pathways influence the manifestation and activity of GLS . MYC exerts its effects through the microRNAs miR-23a and miR-23b that have binding sites in 3UTR of GAC [14C16]. Cells transformed by mutant KRAS demonstrate increased manifestation of glutamine rate of metabolism genes and become reliant on external sources of glutamine [17C19]. It has been reported that proliferation of KRAS mutant pancreatic ductal adenocarcinoma cells depend on glutamine rate of metabolism, which is definitely driven by GLS and downstream transaminases GOT1/2 [20, 21]. GLS has also been shown to be a direct effector of RHO-mediated transformation of breast tumor cells . In addition, synthetic lethal relationships of glutamine rate of metabolism CCT244747 have been reported. For instance, glioblastoma or acute myeloid leukemia (AML) tumors that harbor IDH1/ IDH2 mutations are particularly dependent on the function of the GAC isoform for the anaplerotic replenishment of KG, which is the resource material used to generate the onco-metabolite 2-HG by these mutant enzymes [22C25]. Furthermore, the glutamine transporter ASCT2 has been found to be vital for triple-negative, basal-like breast cancer cell growth . A critical gateway enzyme in glutaminolysis, GLS has been a sought after restorative target for small molecule inhibitors. The earliest approaches were based on glutamine mimetic antimetabolites CCT244747 DON, acivicin, and azaserine [27C29]. Despite moderate preclinical antitumor activity, severe toxicity issues led to discontinuation of the medical development of these molecules . In the last 12 years, two novel glutaminase inhibitors, BPTES and 968, have been profiled extensively in the literature. Both agents specifically inhibit the GLS isoenzyme (both splice variants KGA and GAC) by binding CCT244747 to the protein at unique allosteric sites and have shown antitumor activity in multiple tumor types [31C35]. Very recently, the structural analogs of BPTES, CB-839 and AGX-4769, were found to be more potent GLS inhibitors [36, 37]. CB-839 (Calithera Biosciences) is currently being evaluated in multiple Phase I medical tests in solid and hematological malignancies as a single agent and in combination with an immune checkpoint inhibitor (“type”:”clinical-trial”,”attrs”:”text”:”NCT02071888″,”term_id”:”NCT02071888″NCT02071888, “type”:”clinical-trial”,”attrs”:”text”:”NCT02071862″,”term_id”:”NCT02071862″NCT02071862, “type”:”clinical-trial”,”attrs”:”text”:”NCT02071927″,”term_id”:”NCT02071927″NCT02071927 and “type”:”clinical-trial”,”attrs”:”text”:”NCT02771626″,”term_id”:”NCT02771626″NCT02771626). In this study, we validated GLS like a restorative target in TNBC cells using GLS specific shRNA constructs. We shown that inducible knockdown of GLS in glutamine dependent TNBC cell lines prospects to a decrease in downstream metabolite levels and serious inhibition of cell growth. Metabolite modulation and subsequent anti-proliferative effects induced by GLS knockdown were rescued by both genetic tools and supplementation with KG, a metabolite downstream of GLS. Our findings were recapitulated as inducible knockdown of GLS in tumor xenografts resulted in a similar switch in metabolite levels, suppressed tumor growth or tumor regression. Furthermore, using CB-839 like a pharmacological tool, we shown that inhibition of GLS prospects to a decrease in mTOR activity and an increase in the ATF4 stress response pathway only in responder breast cancer.